Diligence memo · auto-generated · as of July 2, 2026
Immunovant, Inc.
Immunovant, Inc. has raised $450M over 1 round; too few niche peers to rank its valuation yet.
Businessfiled
Immunovant, Inc. operates in Pharmaceuticals, based in NEW YORK.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Immunovant, Inc. has raised $450M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).
Largest single filing: $450M on 2025-01-15.
Most recent recorded round closed around 2025-01-15.
Valuation (modeled)modeled
Provath models Immunovant, Inc. at approximately $5.0B (range $2.9B–$6.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Last raise 18 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 99% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 98% of those peers.
Closest niche peers: Par Health, Inc..
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.